Q-omics provides the consensus-scored SLAIN1 profile across patient tissues and cancer cell-line models. SLAIN1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SLAIN1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SLAIN1 RNA expression shows 18,765 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BRCA, KICH, and KIRP as cancer lineages where SLAIN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLAIN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLAIN1 survival associations across molecular data types. SLAIN1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLAIN1 RNA expression–survival associations across cancer types. High SLAIN1 expression shows favorable associations in BRCA, UCEC, HNSC, MESO, LGG and OV. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SLAIN1 RNA expression.
This table summarizes SLAIN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLAIN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLAIN1 shows lower tumor expression in KICH, THCA, LUSC, LIHC, LUAD and KIRC. The KICH box plot shows higher SLAIN1 RNA expression in normal versus tumor tissue (log2 FC = −1.522, t-test p < 0.001).
This table shows molecular features associated with SLAIN1 in patient tissues and cancer cell lines. In patient samples, SLAIN1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SLAIN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
